Deregulated expression of HDAC9 in B-cells promotes development of lymphoproliferative disease and lymphoma
Open Access
- 1 January 2016
- journal article
- research article
- Published by The Company of Biologists in Disease Models & Mechanisms
- Vol. 9 (12), 1483-1495
- https://doi.org/10.1242/dmm.023366
Abstract
Histone deacetylase 9 (HDAC9) is expressed in B cells, and its overexpression has been observed in B-lymphoproliferative disorders, including B-cell non-Hodgkin lymphoma (B-NHL). We examined HDAC9 protein expression and copy number alterations in primary B-NHL samples, identifying high HDAC9 expression among various lymphoma entities and HDAC9 copy number gains in 50% of diffuse large B-cell lymphoma (DLBCL). To study the role of HDAC9 in lymphomagenesis, we generated a genetically engineered mouse (GEM) model that constitutively expressed an HDAC9 transgene throughout B-cell development under the control of the immunoglobulin heavy chain (IgH) enhancer (Eμ). Here, we report that the Eμ-HDAC9 GEM model develops splenic marginal zone lymphoma and lymphoproliferative disease (LPD) with progression towards aggressive DLBCL, with gene expression profiling supporting a germinal center cell origin, as is also seen in human B-NHL tumors. Analysis of Eμ-HDAC9 tumors suggested that HDAC9 might contribute to lymphomagenesis by altering pathways involved in growth and survival, as well as modulating BCL6 activity and p53 tumor suppressor function. Epigenetic modifications play an important role in the germinal center response, and deregulation of the B-cell epigenome as a consequence of mutations and other genomic aberrations are being increasingly recognized as important steps in the pathogenesis of a variety of B-cell lymphomas. A thorough mechanistic understanding of these alterations will inform the use of targeted therapies for these malignancies. These findings strongly suggest a role for HDAC9 in B-NHL and establish a novel GEM model for the study of lymphomagenesis and, potentially, preclinical testing of therapeutic approaches based on histone deacetylase inhibitors.Funding Information
- Association for International Cancer Research (11-0301)
- Cancer Research UK (A12747)
- Leukaemia and Lymphoma Research (11046)
This publication has 87 references indexed in Scilit:
- MEF2B mutations lead to deregulated expression of the oncogene BCL6 in diffuse large B cell lymphomaNature Immunology, 2013
- Genome-wide association study identifies a variant in HDAC9 associated with large vessel ischemic strokeNature Genetics, 2012
- Inactivating mutations of acetyltransferase genes in B-cell lymphomaNature, 2011
- BLIMP1 Is a Tumor Suppressor Gene Frequently Disrupted in Activated B Cell-like Diffuse Large B Cell LymphomaCancer Cell, 2010
- Guidelines for the welfare and use of animals in cancer researchBritish Journal of Cancer, 2010
- Inhibition of HDAC9 Increases T Regulatory Cell Function and Prevents Colitis in MiceGastroenterology, 2010
- The many roles of histone deacetylases in development and physiology: implications for disease and therapyNature Reviews Genetics, 2009
- Acetylation Is Indispensable for p53 ActivationCell, 2008
- The Rpd3/Hda1 family of lysine deacetylases: from bacteria and yeast to mice and menNature Reviews Molecular Cell Biology, 2008
- Polo-like kinases and the orchestration of cell divisionNature Reviews Molecular Cell Biology, 2004